Sodium alginate as a novel therapeutic option in experimental colitis.
The potential therapeutic effect of low-viscosity sodium alginate (LVA) was studied in a rat model of acute colitis induced by intracolonic administration of acetic acid. This experimental model produced a significant ulcerative colitis. Induction of colitis also significantly enhanced the serum and colonic mucosal cytokine (IL-6 and TNF-alpha) and eicosanoid (LTB4 and PGE2) levels, which paralleled with the severity of colitis. LVA solution was administered orally as drinking water at concentration of 0.5% (W/V) for 1 week. The tolerability and inhibitory effect of LVA on matrix metalloproteinase-2 (MMP-2) were tested using WEHI-164 cell line and zymography method. The results showed that LVA therapy is able to significantly reduce colonic damage score, histological lesion, serum and colonic mucosal IL-6, TNF-alpha, LTB4 and PGE2 levels in treated group compared with nontreated controls. Moreover, in vitro examinations revealed that treatment with LVA could diminish MMP-2 activity. It is concluded that LVA is able to suppress acetic acid-induced colitis in rats. Some of the action of LVA may be associated with its inhibitory effects on cytokine and eicosanoid production and MMP-2 activity. Our data suggest that LVA could potentially be a novel therapeutic option for inflammatory bowel disease.
Mirshafiey
A
A
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. a.mirshafiey@yahoo.com
Khodadadi
A
A
Rehm
B H
BH
Khorramizadeh
M R
MR
Eslami
M B
MB
Razavi
A
A
Saadat
F
F
D000464:Alginates / Q000494:pharmacology*; D000818:Animals; D045744:Cell Line, Tumor; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015232:Dinoprostone / Q000097:blood; D004195:Disease Models, Animal; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D020723:Glucuronic Acid / Q000494:pharmacology*; D006603:Hexuronic Acids / Q000494:pharmacology*; D006651:Histocytochemistry; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007413:Intestinal Mucosa / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D007975:Leukotriene B4 / Q000097:blood; D020778:Matrix Metalloproteinase 2 / Q000276:immunology; D061965:Matrix Metalloproteinase Inhibitors; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000464:Alginates; D006603:Hexuronic Acids; D015850:Interleukin-6; D061965:Matrix Metalloproteinase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D007975:Leukotriene B4; D020723:Glucuronic Acid; D020778:Matrix Metalloproteinase 2; D015232:Dinoprostone